India's First Dual-Target Myeloma CAR-T: BharatBiotech Subsidiary and VeGen Bio Join Forces
BharatBiotech's Nucelion and VeGen Bio partner to manufacture VL-2511, a breakthrough dual-target CAR-T therapy for multiple myeloma in India.
In a landmark move for precision oncology in India, Nucelion Therapeutics, a subsidiary of the renowned Bharat Biotech, has entered into a strategic partnership with Hyderabad-based VeGen Bio. The collaboration aims to establish the clinical manufacturing and commercial production of a groundbreaking cell therapy: the Dual-Target Myeloma CAR-T, known as VL-2511.
This partnership is designed to bridge the gap between scientific discovery and large-scale patient access, focusing on the technology transfer and production of innovative cancer treatments within India.
Targeting Multiple Myeloma: What is VL-2511?
Multiple myeloma is a severe hematological malignancy that presents significant treatment challenges and unmet medical needs for patients across India. To combat this, VeGen Bio has developed VL-2511, a first-in-class autologous CAR-T therapy.
Unlike traditional therapies, VL-2511 is a dual-target therapy designed to simultaneously attack two distinct antigens: BCMA and CD19. This dual-action approach is critical because it addresses "antigen escape"—a process where cancer cells survive by losing or reducing the target antigen that a single-target therapy would normally recognize.
Proven Potential and Global Reach
VL-2511 is currently in Phase II clinical stages and has already established a recommended Phase II dose (RP2D). The therapy has shown exceptional promise in patients with extramedullary disease (EMD) and maintains a favorable safety profile. Its efficacy has already been observed through clinical experience in China, and development is currently ongoing in the United States.
The Role of Nucelion Therapeutics
While VeGen Bio provides the scientific expertise and the therapeutic pipeline, Nucelion Therapeutics acts as the specialized Contract Research, Development, and Manufacturing Organisation (CRDMO). Nucelion will utilize its single-site GMP manufacturing facility to handle the technology transfer and production of VL-2511.
Crucially, Nucelion's facility is designed to meet the stringent regulatory standards of the CDSCO (India), US FDA, and EMA. This means that therapies produced here can be launched not only in India but on a global scale.
"Many CAR-T programs stall between a promising construct and a product that can be made reliably at scale. As one of India’s first dedicated cell and gene therapy CRDMOs, Nucelion closes that gap," said Raghu Malapaka, PhD, CBO of Nucelion Therapeutics.
Driving Down Costs and Increasing Access
One of the primary goals of this collaboration is to improve the economics of advanced cell therapies. By focusing on process optimization, increasing manufacturing yields, and enhancing operational efficiency, the two companies aim to reduce production costs.
Prashant Bhavar, Director of VeGen Bio, emphasized that the ultimate objective is to create an end-to-end ecosystem for cell therapy innovation in India, making these next-generation treatments more affordable and accessible to the people who need them most.
Key Highlights of the Collaboration:
- Focus Area: Therapeutic translation, process development, and manufacturing scale-up.
- Lead Candidate: VL-2511 (Dual BCMA/CD19 CAR-T therapy).
- Infrastructure: Use of a GMP-certified facility meeting international (FDA/EMA) standards.
- Future Scope: The framework will serve as a platform for other cell therapy candidates in VeGen Bio's pipeline.